CytoImmune Therapeutics (Worldwide Rights for Novel EGFR Dual-targeting CAR) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Asset Purch.

  • Financing Rounds
  • 1

CytoImmune Therapeutics (Worldwide Rights for Novel EGFR Dual-targeting CAR) General Information

Description

Worldwide rights for novel EGFR dual-targeting CAR. Chimeric Antigen Receptors (CAR) are fusion proteins that combine an extracellular antigen recognition domain with an intracellular co-stimulatory signaling domain. Natural Killer (NK) cells are modified genetically to allow insertion of a CAR. CAR NK cell therapy has demonstrated initial clinical relevance without the limitations of CAR-T, such as Cytokine Release Syndrome, neurotoxicity or Graft vs Host Disease (GVHD).

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Corporate Backed or Acquired
Corporate Office
  • San Diego, CA
  • United States
Primary Industry
Buildings and Property
Other Industries
Biotechnology
Corporate Office
  • San Diego, CA
  • United States

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CytoImmune Therapeutics (Worldwide Rights for Novel EGFR Dual-targeting CAR) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore CytoImmune Therapeutics (Worldwide Rights for Novel EGFR Dual-targeting CAR)‘s full profile, request access.

Request a free trial

CytoImmune Therapeutics (Worldwide Rights for Novel EGFR Dual-targeting CAR) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore CytoImmune Therapeutics (Worldwide Rights for Novel EGFR Dual-targeting CAR)‘s full profile, request access.

Request a free trial

CytoImmune Therapeutics (Worldwide Rights for Novel EGFR Dual-targeting CAR) FAQs

  • Where is CytoImmune Therapeutics (Worldwide Rights for Novel EGFR Dual-targeting CAR) headquartered?

    CytoImmune Therapeutics (Worldwide Rights for Novel EGFR Dual-targeting CAR) is headquartered in San Diego, CA.

  • What industry is CytoImmune Therapeutics (Worldwide Rights for Novel EGFR Dual-targeting CAR) in?

    CytoImmune Therapeutics (Worldwide Rights for Novel EGFR Dual-targeting CAR)’s primary industry is Buildings and Property.

  • Is CytoImmune Therapeutics (Worldwide Rights for Novel EGFR Dual-targeting CAR) a private or public company?

    CytoImmune Therapeutics (Worldwide Rights for Novel EGFR Dual-targeting CAR) is a Private company.

  • What is CytoImmune Therapeutics (Worldwide Rights for Novel EGFR Dual-targeting CAR)’s current revenue?

    The current revenue for CytoImmune Therapeutics (Worldwide Rights for Novel EGFR Dual-targeting CAR) is .

  • Who are CytoImmune Therapeutics (Worldwide Rights for Novel EGFR Dual-targeting CAR)’s investors?

    Cytoimmune Biologics has invested in CytoImmune Therapeutics (Worldwide Rights for Novel EGFR Dual-targeting CAR).

  • When was CytoImmune Therapeutics (Worldwide Rights for Novel EGFR Dual-targeting CAR) acquired?

    CytoImmune Therapeutics (Worldwide Rights for Novel EGFR Dual-targeting CAR) was acquired on 03-Aug-2020.

  • Who acquired CytoImmune Therapeutics (Worldwide Rights for Novel EGFR Dual-targeting CAR)?

    CytoImmune Therapeutics (Worldwide Rights for Novel EGFR Dual-targeting CAR) was acquired by Cytovia Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process